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Abstract
Background: Cross-sectional studies suggest an association between exposure to ambient air pollution and atherosclerosis.
We investigated the association between outdoor air quality and progression of subclinical atherosclerosis (common carotid
artery intima-media thickness, CIMT).
Methodology/Principal Findings: We examined data from five double-blind randomized trials that assessed effects of
various treatments on the change in CIMT. The trials were conducted in the Los Angeles area. Spatial models and land-use
data were used to estimate the home outdoor mean concentration of particulate matter up to 2.5 micrometer in diameter
(PM2.5), and to classify residence by proximity to traffic-related pollution (within 100 m of highways). PM2.5 and traffic
proximity were positively associated with CIMT progression. Adjusted coefficients were larger than crude associations, not
sensitive to modelling specifications, and statistically significant for highway proximity while of borderline significance for
PM2.5 (P=0.08). Annual CIMT progression among those living within 100 m of a highway was accelerated (5.5 micrometers/
yr [95%CI: 0.13–10.79; p=0.04]) or more than twice the population mean progression. For PM2.5, coefficients were positive
as well, reaching statistical significance in the socially disadvantaged; in subjects reporting lipid lowering treatment at
baseline; among participants receiving on-trial treatments; and among the pool of four out of the five trials.
Conclusion: Consistent with cross-sectional findings and animal studies, this is the first study to report an association
between exposure to air pollution and the progression of atherosclerosis – indicated with CIMT change – in humans.
Ostensibly, our results suggest that air pollution may contribute to the acceleration of cardiovascular disease development –
the main causes of morbidity and mortality in many countries. However, the heterogeneity of the volunteering populations
across the five trials, the limited sample size within trials and other relevant subgroups, and the fact that some key findings
reached statistical significance in subgroups rather than the sample precludes generalizations to the general population.
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Introduction
Cardiovascular disease (CVD) is the most important cause of
morbidity and mortality in the developed world, and atheroscle-
rosis is the central underlying pathology [1]. Atherogenesis is a life-
long process involving a range of mechanisms including lipid
peroxidation and inflammation affecting the vascular wall. The
clinically most relevant results of this pathology are myocardial
infarction and stroke. Evidence for acute cardiovascular effects of
air pollution has substantially increased in recent years; most
experts agree that ambient particulate matter plays a role in
triggering cardiovascular events among those with predisposing
cardiovascular pathologies [2,3]. Experimental studies indicate a
mechanistic role of air pollution in various acute cardiovascular
processes including ischemia, endothelial dysfunction, activation of
the fibrinolytic system and possibly plaque destabilization[2,4].
Far less research has tested the question whether ambient air
pollution also contributes to the development of chronic
pathologies, such as atherosclerosis, that predispose to acute
cardiovascular disease. Animal studies conducted in rabbits, rats or
mice with urban particulate matter instillation and inhalation
experiments, indicate more rapid progression of atherosclerosis
among animals exposed to urban particulate matter (PM)
compared to filtered air [4,5,6,7]. A few cross-sectional studies
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markers of air pollution and the degree of atherosclerosis,
measured with carotid artery intima-media thickness (CIMT)
[8], and both coronary and aortic calcifications [9,10]. To our
knowledge, no study has investigated the impact of ambient air
pollution on the progression of atherosclerosis in humans. Herein
we used longitudinal data available from five randomized
controlled trials to investigate whether chronic exposures to
ambient air pollutants contribute to a faster progression rate of
atherosclerosis in humans. We have previously reported a cross-
sectional analysis of baseline CIMT from two of the five trials in
the current study and observed a significant cross-sectional
association between CIMT levels at baseline and assigned home
outdoor levels of ambient PM2.5 [8]. We added longitudinal data
from three additional trials that have completed two to three years
of average follow-up [11,12,13,14].
Methods
Trials
This study used data from 5 pre-existing clinical trials, all of
which are registered in ClinicalTrials.gov. (a) the B-Vitamin
Atherosclerosis Intervention Trial (BVAIT; NCT 00114400
[http://clinicaltrials.gov/ct2/show/NCT00114400])[14]; (b) the
Vitamin E Atherosclerosis Prevention Study (VEAPS; NCT
00114387 [http://clinicaltrials.gov/ct2/show/NCT00114387])
[15]; (c) the Estrogen in the Prevention of Atherosclerosis Trial
(EPAT; NCT 00115024 [http://clinicaltrials.gov/ct2/show/
NCT00115024]) [12]; (d) the Troglitazone Atherosclerosis Re-
gression Trial (TART [NCT 00116545; http://clinicaltrials.gov/
ct2/show/NCT00116545]) [11]; and (e) the Women’s Estrogen-
Progestin Lipid-Lowering Hormone Atherosclerosis Regression
Trial (WELL-HART; NCT 00000559 [http://clinicaltrials.gov/
ct2/show/NCT00000559]) [13]. Table 1 summarizes the main
characteristics of these trials and more details are given elsewhere
[11,12,13,14,15]. (For exclusion criteria of each trial, see
supplemental material, Table S2). All trials were conducted with
adult volunteers. Inclusion criteria differed for each trial according
to the primary hypothesis and the intervention of interest, namely
testing the anti-atherogenic property of hormone replacement
therapy [12,13], vitamin supplementation [14,15], and a diabetes
treatment [11]. All clinical trials used in these analyses were
approved by the institutional review board of the University of
Southern California (USC).
For our study, the main outcome of interest is the change over
time in the carotid artery intima-media thickness (CIMT).
Repeated measurements of CIMT are a well-established non-
invasive method to test the effect of interventions on atheroscle-
rosis. In all trials, high-resolution far-wall B-mode ultrasound
images of the right common carotid artery (CCA) to measure far
wall CIMT were obtained at baseline prior to randomization to
treatment, and every 6 months thereafter for the duration of the
trials, using the same ultrasound hardware and software and
ultrasonographers during the full follow-up. Details of this
highly-reproducible method are published [15,16,17]. Blood
pressure, height and weight were measured using standard
procedures. The baseline questionnaires included an assessment
of all major cardiovascular disease risk factors and potential
confounding variables. The current residential address was
available for each subject. Fasting blood samples were drawn
for lipid measurements. Data used in our analyses were collected
uniformly with the same instruments in each trial. We used two
main markers of exposure to ambient air pollution to assign
long-term residential exposure to each subject, namely the
modeled average home outdoor level of PM2.5 and the distance
of the residence from traffic corridors, a widely used marker of
exposure to unmeasured traffic-related pollutant concentrations
[18].
Table 1. Description of the B-Vitamin Atherosclerosis Intervention Trial (BVAIT), the Vitamin E Atherosclerosis Prevention Study
(VEAPS), the Estrogen in the Prevention of Atherosclerosis Trial (EPAT), the Troglitazone Atherosclerosis Regression Trial (TART), and
the Women’s Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) used in this analyses.
Characteristic BVAIT VEAPS EPAT TART WELLHART
Year (start / end of trial) 2001 / 2006 1996 / 2000 1994 / 1998 1997 / 2000 1995 / 2000
Mean (range) follow-up duration
in yrs
3.3
(0.5–5.1)
2.8
(0.5–3.5)
1.8
(0.4–2.4)
1.8
(0.4–2.4)
2.9
(0.4–4.0)
N at baseline 506 353 222 299 226
N with progression & outdoor
PM2.5 data
475 350 169 275 214
Mean age (range) at baseline 61.4
(40–89)
56.2
(40–82)
61.4
(47–80)
52.6
(30–71)
63.7
(49–76)
On-trial Intervention (tx) Vitamin B Vitamin E (a-
Tocopherol)
Unopposed
estrogen
Troglitazone (thiazolidinedione) Estrogen/Estrogen-
Progestin
Main inclusion Criteria
Sex Men & post-
menopausal Women
Men & Women Postmenopausal
women
Men & Women Postmenopausal
Women
Age .40 yrs .40 yrs $45 yrs 30–70 yrs #75 yrs
Other fasting plasma
homocysteine
$1.15 md/dL
LDL .130 mg/dL LDL $130 mg/dL diagnosed w/ type 2 diabetes mellitus
onset at $30 yrs of age; fasting glucose
.140 mg/dL & ,350 mg/dL; receiving
,150 units insulin/day.
LDL=100–250 mg/
dL; $1 coronary
artery lesion
Main reference Hodis et al, 2009
[14]
Hodis et al, 2002,
[15]
Hodis et al, 2001,
[12]
Hodis et al, 2006, [11] Hodis et al, 2003,
[13]
(CVD = cardiovascular diseases; LDL = low density lipids). For exclusion criteria: see Table S2 in the online supplement.
doi:10.1371/journal.pone.0009096.t001
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Estimates of the home outdoor mean PM2.5 concentrations
were assigned as described in our previous cross-sectional analysis
[8,19]. In brief, a PM2.5 surface was derived from a geo-statistical
model with data derived from 23 state and local district
monitoring stations (year 2000). To assign exposure, PM2.5 data
were interpolated using a combination of a universal kriging model
with a quadratic drift and a multiquadric radial basis function
model [20,21]. These models do not take into account local
information such as traffic density or other metrics. We averaged
the two surfaces based on 25-meter grid cells. We linked the
address of each subject with the exposure surface through a geo-
coding database (www.esri.com). All models were implemented
with ArcScript from the Environmental Systems Research
Institute (ESRI, Redlands, CA).
Distance to highway or main road
In line with the known spatial distributions of traffic-related
pollutants and previously published studies, we defined the 100-
meter corridor along highways as a ‘high exposure zone’. Those
23 subjects (1.5% of all) living further than the 100-meter corridor
are assumed to have ‘background’ level exposure to these same
pollutants [18]. To increase the number of subjects falling into the
‘high exposure zone’ and provide comparability with other studies
examining cardiovascular endpoints [22,23], we also used proximity
to highways (100 m) or living within 50 m of a major road as a marker of
exposure. Traffic density, and in particular diesel truck density, is
much lower on main roads than on highways; thus, these 238
‘exposed’ subjects (16.1%) experienced, on average, lower
concentrations of traffic-related pollutants than the subset living
within 100 m of highways.
Statistical models
To make use of the complete follow-up data, missing covariate
data were imputed employing standard methods [24]. The missing
data structure and the particular method of imputation we used
are described in the supplement (Text S1 and Table S1). As a
result, all models used the same complete data set of N=1483.
The main model presented in the results included only 5 subjects
with one or more imputed covariates. Thus, results among those
with complete data and the total sample including the five were
identical.
Our main outcome was the annual rate of change in CIMT,
derived for each subject as the slope coefficient from the linear
regression across all CIMT measurements against follow-up time
(in years). Using this outcome variable, we fitted separate linear
regression models for PM2.5 and road proximity metrics, adjusted
for baseline covariates. Beta coefficients are expressed as the
annual change in CIMT (micrometers/year) per a 10 ug/m
3
contrast in PM2.5 and for living in proximity to a highway or main
road (yes/no). While treatments differed across the trials, all
studies investigated the potential effects of treatment on CIMT
progression. Thus, all models included one indicator variable to
control for treatment. We explored the sensitivity of the results to
adjustment for several sets of covariates, including trial. Given that
the causal paths linking pollution with atherogenesis may be
complex, we also evaluated the impact of adjustment for co-
variates that may be markers of factors on the causal paths, e.g.
hypertension, physical activity, overweight, menopause and others.
The impact of adjustment for CIMT at baseline was also tested,
and trial was alternatively included as a fixed and random effect,
respectively. While we present results for a range of models, we
chose a parsimonious model as the ‘main model’, with adjustment
for treatment status, smoking, wine consumption, height, educa-
tion, and reported lipid lowering treatments.
Since our data came from five different trials with different
inclusion criteria, we also analyzed each trial separately and then
combined the results using a random-effects meta-analysis [25].
Results presented in the figures utilized this approach. We tested
heterogeneity of the estimates using the Cochran’s chi-square test
or Q-test.
Our previously published cross-sectional findings from two trials
gave some indication of possibly different associations between air
pollution and baseline CIMT among subgroups defined by sex,
age, and history of lipid-lowering therapy (taken as a marker for
being at greater risk for atherosclerosis). In our longitudinal
analyses, interactions of the main effects of each of the exposures
with these factors were tested. We also tested whether the main
effects differed by on-trial treatment and by markers of socio-
economic status (income and education level). Several U.S. air
pollution studies observed larger effects of pollution among socially
disadvantaged groups [19].
We also present ‘‘two-pollutant models’’ with both PM2.5 and
highway proximity included in the model, assuming that the two
markers may capture different (interrelated) aspects of ambient air
pollution, namely urban background pollution (mostly due to
secondary pollutants) and the near-source traffic-related pollutants
with higher concentrations of primary pollutants.
Results
Table 2 presents the main analytic variables for the populations
of each trial. As expected, the heterogeneous inclusion criteria
across the five trials result in several differences between trials. As
usual in longitudinal CIMT studies of only a few years, CIMT
progressed, on average, but decreased in many subjects. The mean
annual progression of CIMT was 2.04 mm/year (standard
deviation of 612.91 mm/year). While home outdoor PM2.5
concentrations were comparable across trials, none of the EPAT
subjects lived within 100 m of a highway.
The main results regarding air pollution and CIMT progression
are presented in Table 3, Figure 1 and Figure 2. In general, both
proximity markers of exposure and P2.5 were positively associated
with CIMT progression. In the total sample, associations were
statistically significant for proximity to highways and of borderline
significance for both, PM2.5 (P-value =0.8) and living within
100 m of a highway or 50 m of a main road (p-value: 0.07; see
Table 4). For those living within 100 m of a highway (N=23), the
CIMT progression was 5.62 mm/year (95% CI: 0.31–10.94;
unadjusted model) and 5.46 mm/year (95%CI: 0.13–10.79; main
model) faster than among those living further away (Figure 2). As
expected, defining a less extremely polluted group as ‘‘exposed’’
(i.e. those living within 50 m of a main road or within 100 m of a
highway; N=238), the main model coefficient was lower (1.64;
95% CI: 20.15 to 3.42) (see Table 4). An increase of 10 mg/m3 in
the home outdoor PM2.5 concentration was associated with a
statistically insignificant 1.74 and 2.53 mm/year faster progression
in CIMT in the unadjusted and the main adjusted model,
respectively (Figure 1).
Main effect estimates were not appreciably altered by inclusion
or exclusion of a range of covariates or adjustment for baseline
CIMT, and adjusted coefficients were without exception slightly
larger than the crude associations. Baseline CIMT and progression
were mildly negatively correlated (r=20.09; p,0.01). Adding
both, PM2.5 and proximity to a highway to the main model had
little impact on the coefficients although confidence intervals
slightly increased (Table 3).
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PM2.5 data (N=1483).
Characteristic BVAIT VEAPS EPAT TART WELLHART TOTAL SAMPLE
(N=475) (N=350) (N=169) (N=275) (N=214) (N=1483)
CIMT at baseline in mm
(mean 6sd; range)
0.7560.14 0.7660.13 0.7660.13 0.8260.15 0.8460.20 0.7860.15
(0.50–1.51) (0.55–1.26) (0.51–1.55) (0.53–1.36) (0.55–2.09) (0.50–2.09)
CIMT progression / yr in mcrm
(mean 6sd; range)
2.5067.47 2.8568.46 0.68615.55 4.71621.22 22.68610.63 2.04612.91
(224.90, 28.43) (231.54, 29.86) (235.15, 49.56) (234.27, 40.65) (244.08, 43.09) (244.08, 49.56)
PM2.5 mean 6sd; (25th–75th percentile) 20.1262.82 20.6662.19 21.2062.09 21.8761.10 20.8062.44 20.7962.37
(19.22–21.94) (20.28–21.84) (20.92–22.08) (21.51–22.53) (20.69–22.11) (20.49–22.05)
Living within 100 m of highway, N (%) 9 (1.89) 5 (1.43) 0 (0.00) 7 (2.55) 2 (0.93) 23 (1.55)
Living within 100 m of highway or
within 50 m of a main road, N (%)
70 (14.74) 50 (14.29) 23 (13.61) 59 (21.45) 36 (16.82) 238 (16.05)
Age; mean 6sd; (range) 61.3869.93 56.1968.94 61.3566.82 52.5668.96 63.6666.47 58.8569.57
(40.21–88.59) (39.55–82.03) (48.00–80.00) (29.72–70.95) (49.00–76.00) (29.72–88.59)
% Women 39.37 52.00 100.00 67.27 100.00 63.18
% Women in menopause 100.00 66.11 100.00 73.51 100.00 68.17
Highest Education (%)
HS graduate or less 6.54 7.71 14.79 82.18 60.56 29.57
Trade/Some College 33.54 35.43 49.11 12.00 29.58 31.2
Bach. Degree or above 59.92 56.86 36.09 5.82 9.86 39.23
Income (%)
,20K $ 8.09 9.33 29.61 79.05 62.37 31.11
20–59K $ 35.06 46.94 48.68 18.58 31.18 35.97
60K+ $ 56.85 43.73 21.71 2.37 6.45 32.92
Under lipid lowering treatment (%)
(any time during trial period)
14.53 18.29 60.95 29.09 43.46 27.58
Race (%)
White 65.68 72.86 57.74 4.73 30.05 50.03
Hispanic 10.74 10.86 22.02 89.09 45.54 31.6
Other 23.58 16.29 20.24 6.18 24.41 18.37
Smoking Status
% Never smoker 63.29 64.29 49.11 65.82 49.53 60.39
% Current smoker 3.38 4.00 0.00 11.27 11.21 5.74
% Former smoker 33.33 31.71 50.89 22.91 39.25 33.87
Packyrs, mean 6sd (range) 6.3613.8 7.86617.25 8.10615.85 6.74615.23 10.60621.36 7.55616.39
(0–92) (0–135) (0–78) (0–99) (0–126) (0–135)
Height (mean 6sd; range); in meters 1.7060.10 1.6960.10 1.6060.07 1.6060.10 1.5560.07 1.6560.11
(1.36–1.94) (1.42–1.98) (1.40–1.80) (1.37–1.92) (1.27–1.70) (1.27–1.98)
BMI (mean 6sd; range) 28.1964.97 27.6864.7 28.8665.41 32.1965.93 30.3965.58 29.2165.49
(4.97–16.76) (4.7–16.12) (5.41–18.4) (5.93–19.37) (5.58–18) (5.49–16.12)
LDL cholesterol (mean 6sd; range) mg/dL 128.79630.38 147.43626.41 162.85626.39 99.59629.46 146.23638.69 134.37636
(56.4–315.6) (61.2–277.8) (90–256) (25–198.8) (56–280) (25–315.6)
Cholesterol (mean 6sd; range) mg/dL 212.2634.75 231.03630.88 247.55631.39 171.04634.14 234.24644.11 216.28642.55
(121–437) (125–394) (162–342) (94–330) (127–392) (94–437)
Physical activity (in Met Cal) mean 6sd;
(range)
2904.776630.85 2854.96725.57 2380.736704.08 2821.186727.67 2841.236696.44
(1466.9–5559.0) (1196.9–6269.9) (389–3641) (1600.1–5988.0) (389–6269.9)
Diastolic blood pressure, mean 6sd
(range); mmHg
79.8268.29 76.6969.32 77.667.56 76.1969.41 76.48610.16 77.6769.08
(58–119.5) (45–103) (57–95) (56–109) (51–117) (45–119.5)
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investigation of possible interactions between air pollution and
other factors. The association of CIMT with ‘proximity to
highways’ as well as with ‘proximity to highways (100 m) or a
main road (50 m)’ was substantially larger and statistically
significant among the socially deprived (as measured by low
income). These effect modifications were statistically significant (p
for interaction ,0.05). A similar pattern emerged for PM2.5 but
associations and interactions were not statistically significant
(Table 4). Stratification by randomization status (active interven-
tion vs. placebo) revealed larger and statistically significant
coefficients for both, proximity to highways (100 m) and PM2.5,
among the subjects randomized to active treatments. For the
highway proximity, this interaction was statistically significant.
The coefficients in the placebo group were not statistically
significant and were five to ten times smaller relative to the
treatment group (see Table 4 and Figure 3 & 4).
Associations did not differ by sex, lipid-lowering treatment, and
ethnicity (Table S3 in supplement). Figures 1, 2, 3 and 4 show the
main results by trial and the respective meta-analytic estimates.
While air pollution coefficients appeared to be different across
trials, power was low to formally test heterogeneity. To get an
impression of the impact of pooling diverse trials we tested the
main model in all possible combinations of pooling only four of the
five trials. As shown in Table S3 (supplement), BVAIT and
TART, in opposing directions, appeared to be the most influential
trials. Namely, in an analysis based on only four trials, excluding
BVAIT data, the size of the coefficients almost doubled, with
significant adjusted coefficients for both, PM2.5 (5.27; 95% CI:
0.73, 9.80; p=0.02) and highway proximity (9.14; 1.33 to 16.96;
p=0.02; Table S3); excluding instead TART data resulted in the
smallest coefficients (Table S3).
Discussion
This is the first study in humans to investigate the association
between markers of exposure to ambient air pollution and the
progression of CIMT, an accepted measure of the progression of
atherosclerosis [26,27]. CIMT results from the cumulative
atherogenic processes that occur in the artery wall. As such,
CIMT progression is associated with future clinical cardiovascular
events [26,28,29]. Our data indicate that the progression of sub-
clinical atherosclerosis correlates with home outdoor air quality,
with particularly strong associations among those living along
Characteristic BVAIT VEAPS EPAT TART WELLHART TOTAL SAMPLE
(N=475) (N=350) (N=169) (N=275) (N=214) (N=1483)
Systolic blood pressure mean 6sd
(range); mmHg
128.66614.66 128.03616.49 127.99614.07 130.86619.09 141.74621.49 130.73617.62
(95.5–178.5) (91–189) (94–161) (89–180) (89–230) (89–230)
doi:10.1371/journal.pone.0009096.t002
Table 2. Cont.
Table 3. Difference in CIMT progression (in micrometers per year) associated with a 10 ug/m
3 contrast in PM2.5 and ‘living within
100 meters of a highway, respectively.
Covariates included in model PM2.5 Within 100 m of traffic
Coeff 95% CI p-value Coeff 95% CI p-value
1-Pollutant models
No covariates (crude association) 1.74 21.04, 4.51 0.219 5.62 0.31, 10.94 0.038
Baseline IMT 1.96 20.82, 4.74 0.167 5.84 0.53, 11.16 0.031
On-trial treatment status 1.75 21.02, 4.52 0.216 5.50 0.19, 10.81 0.042
On-trial treatment status, smoking, education 2.11 20.72, 4.95 0.144 5.89 0.55, 11.23 0.031
Above + lipid lowering tx 2.43 20.4, 5.26 0.092 5.63 0.3, 10.95 0.038
Treatment status, smoking, wine consumption, height, education, lipid
lowering tx (MAIN MODEL)
2.53 20.31, 5.38 0.081 5.46 0.13, 10.79 0.044
MAIN + baseline IMT 2.64 20.20, 5.49 0.069 5.59 0.27, 10.92 0.040
MAIN + MET cal, menopause, diabetes, ETS work 1.91 20.94, 4.77 0.189 5.40 0.1, 10.71 0.046
Above + HDL, high blood pressure 1.96 20.9, 4.82 0.179 5.35 0.05, 10.66 0.048
MAIN + ‘trial’ as fixed effect 1.16 21,71, 4.02 0.428 5.18 20.10, 10.46 0.054
MAIN + ‘trial’ as random effect 1.29 21.57, 4.15 0.377 5.21 20.07, 10.49 0.053
2-Pollutant models (PM2.5 and proximity to traffic):
MAIN MODEL 2.40 20.44, 5.24 0.098 5.25 20.08, 10.58 0.054
MAIN + ‘trial’ as fixed effect 1.30 21.55, 4.15 0.371 5.00 20.28, 10.29 0.064
MAIN + ‘trial’ as random effect 1.43 21.42, 4.28 0.324 5.04 20.24, 10.32 0.062
All models are based on the total population (N=1483).
doi:10.1371/journal.pone.0009096.t003
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traffic density (i.e. several hundred-thousand vehicles per day) –
several fold higher then on main surface roads – and most
highways are designated truck routes. Moreover, trucks are the key
source of diesel particles while passenger cars operate primarily
with gasoline in North America. These features may explain the
extreme gradients in ultrafine particles and other primary
pollutants observed along Southern California highways with
some ten-fold concentrations reported within the first 30 meters as
compared to the background levels measured at .150–200 meters
[18]. In line with the difference in traffic density – thus lower
pollution - our finding of smaller effect estimates if the ‘exposed’
included 215 subjects living within 50 m of a main road is
plausible.
While our progression findings have not been previously
reported, the results agree with cross-sectional observations in
humans [8,9] and with several prospective animal experiments
where rats, mice, and rabbits exposed to ambient particulate
matter developed atherosclerotic plaques and calcification
[5,6,7,30]. These animal studies – one placing mice adjacent to
a Southern California highway [6] – reported a range of effects
relevant to atherogenesis and significant progression of athero-
sclerosis, which was possibly modified by endogenous or
exogenous factors such as genetics and diet [7].
Despite pooling five trials, the major weakness of the study
remains the limited sample size. The percent of people living very
close to highways is small, in general, and was only 1.6% in our
more affluent population. Thus, the strongest results relied on only
23 ‘exposed’ subjects (i.e. within 100 m of a highway). In contrast,
results of the PM2.5 analyses were not affected by this limitation as
this exposure metric is defined on a continuous scale. The PM2.5
estimates did not reach statistical significance in the full data, but
were clearly significant among the pool of four instead of five
studies (excluding BVAIT) as well as among the on-trial treatment
group. In fact, the most intriguing and challenging aspect of our
results are the sub-group findings. All subgroups tested were
identified a priori, based on prior studies and hypotheses, and the
confirmation of modifiers of effects underscores the plausible
notion that there exist groups who are more susceptible to
oxidative and inflammatory air pollutants. In line with other U.S.-
based air pollution studies, the effects were stronger among the
socioeconomically disadvantaged, a possible marker for concom-
itant adverse environmental exposures, poor diet, and a more
stressful life [19].
In line with our previous cross-sectional findings, proximity to
highways appeared to be more strongly related to CIMT
progression in women but the difference did not reach statistical
significance (Table S3 in the supplement). With the limited sample
size, it was however difficult to evaluate this further. Similarly, to
evaluate whether the apparent but not significant differences in the
trial-specific estimates reflect differences in the distribution of
susceptibilities among the populations, larger sample size would be
needed. The trials had high levels of quality control and identical
standards that yield a high degree of comparability in the CIMT
data across all five trials [17,26]. However, the different objectives
and consequent recruitment procedures of each trial – all based on
volunteers – increases the inherent heterogeneity in our data and
limits our ability to generalize results.
The interaction between randomized ‘treatment on trial’ and
the atherogenic effect of air pollution was apparently present
across heterogeneous interventions ranging from vitamins (VEAPS
and BVAIT) to the regulation of diabetic metabolism (TART) and
hormones (EPAT and WELL-HART) (Figures 3 and 4). Given the
double-blind randomized design applied in all trials, and treatment
status indeed not being associated with pollution it is not very
plausible to explain the interaction finding as chance alone.
With the exception of WELLHART, treatments affected CIMT
progression in all trials although not necessarily in the entire
populations [11,12,13,14,15]. This means that the treatments did
affect vascular metabolism and homeostasis in a way that resulted
in changes in the artery wall structure, measured with CIMT
progression. Periods of metabolic change may be a vulnerable
window in the presence of other pro-atherogenic factors [31], such
as hypothesized for ambient particulate matter [2,4,32]. All
interventions used in these trials have both pro- and anti-
atherogenic properties, and the postulated oxidative and inflam-
matory effects of ambient air pollutants may interact with the
metabolic effects of these interventions in a complex manner.
Figure 1. Association (with 95% CI) between a contrast in
10 ug/m
3 home outdoor PM2.5 and CIMT progression by trial
and the respective meta-analytic estimates. The X-axis indicates
the regression coefficient (change) in micrometers. Studies: B = BVAIT,
E = EPAT, T = TART, V = VEAPS, W = WELLHART. The solid line
indicates the level of no effect.
doi:10.1371/journal.pone.0009096.g001
Figure 2. Associations (with 95% CI) of living within 100 m of a
highway and CIMT progression by trial and the respective
meta-analytic estimate. The X-axis indicates the regression coeffi-
cient (change) in micrometers. Studies: B=BVAIT, T=TART, V=VEAPS,
W=WELLHART. Among the EPAT participants, no subject lived within
100 m of a major road. The solid line indicates the level of no effect.
doi:10.1371/journal.pone.0009096.g002
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ambient particulate matter on atherogenesis were stronger among
those fed with a high fat chow as compared to those under a
normal diet [7]. One would need larger studies to corroborate
these interactions for the various on-trial treatments. Moreover,
the interaction by treatment status was only apparent for PM2.5
and ‘living close to highways’ (with 23 subjects ‘exposed’), but not
so for ‘living close to highways or main roads’. In light of this
inconsistency, one may question a causal interpretation of the
observed effect modification due to treatments. However, as
mentioned above in the Methods, living within 50 m of main
roads includes 215 subjects in the ‘exposed’ group with lower
traffic-related pollution than those 23 participants living within
100 m of a highway. Thus, effect stimates would be expected to be
smaller. Statistical power to evaluate interactions for this marker of
exposure is not sufficient.
Similarly, due to limited sample sizes, the statistically significant
interaction between on-trial treatment and the effects of traffic-
related pollution cannot be evaluated further in each trial
separately. Thus, it is not clear whether the same interactions
would prevail in larger studies or be restricted to a few on-trial
treatments. Below, we conjecture about explanations of this
interaction trial by trial.
Air pollution associations were strongest in TART with only
slightly larger associations in the treatment group. All TART
subjects were patients with type 2 diabetes – a pathology with a
well known atherogenic propensity and with some preliminary
evidence of higher susceptibility to adverse cardiovascular effects
of air pollution [4,11]. The trial tested a peroxisome proliferator-
activated receptor agonist (PPARc), namely thiazolidinedione
Figure 3. Associations (with 95% CI) of living within 100 m of a
highway and CIMT progression and the respective meta-
analytic estimates among the on-trial placebo group (treat-
ment group: see Figure 4). EPAT: no subject lived within 100 m of a
highway. The X-axis indicates the regression coefficient (change) in
micrometers. The solid line indicates the level of no effect. Studies:
B=BVAIT, T=TART, V=VEAPS, W=WELLHART.
doi:10.1371/journal.pone.0009096.g003
Figure 4. Same as Figure 3, but for the on-trail treatment
group.
doi:10.1371/journal.pone.0009096.g004
Table 4. Association between both markers of air pollution and CIMT progression among subgroups.
Subgroups PM2.5 within 100 m traffic
within a highway (100 m)
OR within a major road (50 m)
Coeff 95% CI p-value p-inter Coeff 95% CI p-value p-inter Coeff 95% CI p-value p-inter
Total sample (same as Table 3)
(N=1483)
2.53 20.31, 5.38 0.081 N/A 5.46 0.13, 10.79 0.044 N/A 1.64 20.15, 3.42 0.072 N/A
By Treatment group
(trial treatment):
Placebo (N=706) 0.88 23.16, 4.92 0.670 0.457 0.96 26.20. 8.12 0.793 0.046 1.88 20.65, 4.41 0.146 0.707
Treatment (N=777) 4.37 0.37, 8.37 0.032 11.43 3.46, 19.39 0.005 1.40 21.12, 3.92 0.277
By income:
Less than 20K (N=429) 4.55 25.07, 14.16 0.354 0.446 13.61 2.17, 25.04 0.020 0.037 6.13 2.32, 9.94 0.002 ,0.001
20K+ (N=950) 1.91 20.67, 4.49 0.146 1.21 24.22, 6.65 0.662 21.49 23.38, 0.39 0.120
By education:
Some high school (N=438) 3.02 27.67, 13.7 0.579 0.614 12.23 1.47, 22.99 0.026 0.053 5.32 1.16, 9.47 0.012 0.001
Trade/some college & bachelor or
graduate (N=1043)
2.13 20.38, 4.63 0.096 0.58 25.23, 6.39 0.846 20.57 22.37, 1.22 0.530
Coefficients are in micrometers, per 10 ug/m
3 PM2.5; ‘living within 100 m of a highway’ (N=1.55%); and ‘living within 100 m of a highway or within a major road (50 m)’
(N=238), respectively. (main model as in Table 3). P-inter is the p-value under the null hypothesis that the main effects are the same in the two subgroups.
doi:10.1371/journal.pone.0009096.t004
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cellular proliferation and migration, and expression of cellular
adhesion molecules. However, the stimulation of macrophages
into foam cells by promoting lipid uptake is a known pro-
atherogenic property of PPARc activation. These effects may
dominate if exposure to air pollution is increased, e.g., recruitment
of precursors of macrophages as observed in rabbits [5] or the
oxidation of lipids [6,33]. As shown in TART, the balance
between pro- and anti-atherogenic effects of TZD depends on host
factors and this may hold true for the interaction with air pollution
as well. In fact, TZD had protective effects only among those with
advanced atherosclerosis (i.e. thicker CIMT) at baseline, and the
considerable heterogeneity of responses to TZD supports the
notion of complex interactions between exogenous factors (e.g.
TZD or air pollution) and reactions in the vascular bed [34].
VEAPS tested the atherogenic effects of vitamin E supplemen-
tation. While known as an anti-oxidant, vitamin E also has pro-
oxidant and pro-atherogenic effects, and those appeared to
dominate in the treatment group where CIMT progression was
4.0 versus only 2.3 micrometers per year in the placebo group
(p=0.08) [15]. Oxidized vitamin E may act as a pro-oxidant in the
artery wall and these proatherogenic properties may be amplified
by pro-inflammatory effects of air pollution. Similarly, interactions
between treatment (vitamin B), other endogenous factors and
environmental effects may apply to BVAIT; effects of vitamin B
were limited to individuals with elevated baseline homocysteine
levels. Homocysteine is linked to atherogenic pathways, and
interactions between ambient air pollution and homocysteine have
been reported previously [35].
EPAT tested the effects of unopposed estrogen replacement
therapy (ERT) with 17-beta-estradiol among postmenopausal
women [12]. ERT significantly reduced CIMT progression by 5
micrometers per year, but this beneficial effect was seen only in
women who did not receive lipid-lowering treatment, namely with
statins whereas among this latter group, CIMT changed far less
during the EPAT follow-up. Whether the somewhat larger PM2.5
coefficient in the treatment group was a chance finding, and how it
interacted with lipid-lowering treatment cannot be determined
with the available sample size. However, it is well known that the
atherogenic effects of hormones underlie rather complex mecha-
nisms which depend on a range of host factors including time since
menopause, concomitant diseases, or type, dose and route of drug
administration [36].
The WELLHART trial tested hormones in women with
established coronary artery disease, at a later stage of menopause
[13]. While treatment had no effect on coronary artery
atherosclerosis, the interaction of air pollution with on-trial
treatment status was also substantial in this population. The
interaction between hormonal factors, ambient air pollutants, and
atherogenesis needs further investigation.
An interesting finding is the similarity of coefficients from the
one-pollutant and two-pollutant models. As mentioned in
Methods, the derivation of the PM2.5 surface did not include
any markers of local traffic while the proximity measures capture
this local exposure space. Thus, the two-pollutant model results
suggest independent associations of ambient PM2.5 (albeit not
statistically significant in all groups) and proximity to traffic with
atherosclerosis (Table 3). This is in line with two different
interpretations. First, it supports the idea that different compo-
nents of the complex mixture contained in urban air pollution act,
in part, independently through complementary mechanisms
[4,32]. Proximity to highways may be a marker for exposure to
high loads of ultrafine particles and other highly redox-active
pollutants, in particular diesel particles [37], and constituents
affecting the airways and alveoli leading to systemic inflammatory
responses [38] and atherogenesis [6]. The larger particles (i.e.
PM2.5) may result in inflammatory reactions in the small and
upper airways alike, and both types of pollution may indepen-
dently enhance systemic inflammation [38]. Second, the indepen-
dent effects may indicate that both exposure assessment approach-
es capture similar types of pollution but on different spatial scales
and concentration levels; ‘proximity’ would characterize the most
extreme local conditions (hot spots) while PM2.5 captures the
additional contrast occurring between geographic areas [37]. In
contrast to other areas, e.g. the U.S. East coast, PM2.5 in the Los
Angeles area, is to a large extent the consequence of primary and
secondary pollutants from traffic, and the proximity measure is, by
definition, a marker for traffic-related exhaust emissions and/or
re-suspended local pollutants. The results, therefore, point in the
direction of traffic-related pollution being an atherogenic health
hazard. This is in line with the Southern Californian animal
studies where experimental chambers were placed adjacent to a
highway. The traffic-related particles enhanced atherogenesis in
mice [6].
Longitudinal analyses of change in biologic markers raise some
contentious statistical issues with regard to the adjustment for the
CIMT levels observed at baseline [39,40]. Our model estimates
were not appreciably altered by adjustment for baseline CIMT
and results were very stable across a range of modelling
assumptions; thus, the findings are unlikely the result of modelling
artefacts. In general, we used baseline covariate information to
adjust the multivariate models rather than the change in some of
these variables. However, individual follow-up time was fairly
short (2–3 years); thus, change in lifestyles or other factors are not
expected to be substantial. We have some indirect evidence that a
potential change in an important lifestyle, namely giving up
smoking during follow-up, was probably not relevant in our
analyses; associations of pollution with CIMT progression was not
different in smokers, and only 6% of participants were smokers at
baseline.
Our analyses do also not take into account possible changes in
exposure due to change in pollution levels over time. Exposure was
assigned based on the year 2000 information. While levels of
pollution fluctuate year by year, with general downward trends,
over decades, the key question relevant for our analyses is whether
the spatial contrasts of the year 2000 would reflect those of other
years. Fortunately, spatial contrasts are more stable over time and
many long-term air pollution studies capitalize on the fact that
spatial contrasts and traffic data of a specific year will properly
approximate exposure contrasts for several years. We are unable
to investigate the possible impact of this type of exposure
misclassification because departure of assessment from the year
2000 is, in our case, a correlate of trial as each trial took place in
different periods (shown in Table 1). As discussed, trials are
inherently different in many other respects.
We had no noise data available, thus, a full assessment of the
correlations between noise and pollutants – in some studies
reported to be lower than expected [41] – was not possible, nor
could we evaluate the potential confounding of traffic-relate noise.
Future studies should investigate this in more detail.
We were also not able to integrate in the exposure assignment
changes in residence that may have occurred during the trial
follow-up. This information was not available nor could we
approach all former participants as some trials happened several
years ago. However, six years of residential history was available
among a subsample of 245 subjects. The vast majority (N=210)
had not moved for six years; we therefore conclude that exposure
misclassification due to ignored moving patterns were not a major
Pollution and Atherogenesis
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jointly correlated with CIMT progression and air pollution at the
address used in our exposure assignment, thus, biases from this
exposure misclassification would be expected to go toward null.
CIMT is the earliest detectable anatomic change in the
development of atherosclerosis and progression of CIMT is
predictive of clinical cardiovascular events [28,29]. The magnitude
of our effect estimates was similar to the effects of on-trial
treatments on CIMT progression. Comparison is, however,
hampered by the differences in absolute progression between
trials due to the differences in inclusion criteria. The mean effect of
a 5.4 micrometer greater progression per year among those living
within 100 m of busy roads or per 23 ug/m
3 contrast in PM2.5 is
approximately twice the average progression as observed across
these trials. Our results for a 10 ug/m
3 contrast in PM2.5 being
associated with 2.5micrometer (total data) to 4.4micrometer
(treatment groups) increase in annual CIMT progression would
translate into 10–30% higher rates in coronary events [26]. This is
well within the range of the results reported by the Women’s
Health Initiative where cardiovascular events increased by 24%
(95%CI: 9–41%) for the same contrast of 10 ug/m
3 ambient
PM2.5 [42]. While these studies and settings are different, our
observed effect appears to be of biologically plausible size [13].
Interactions between anti-atherogenic treatments such as lipid-
lowering prescriptions and ambient air pollution may be a major
concern and research challenge as some treatments may influence
mechanisms relevant in the effects of air pollution. As we used
existing data we were unable to fully investigate whether such
prescriptions taken at baseline or during follow-up or both
interacted with the main effects. As shown in the supplement
(Table S3), subjects reporting lipid-lowering treatments at study
entry showed substantially stronger associations between CIMT
progression and pollution than those without such treatments or
those who newly received lipid lowering prescriptions during the
follow-up period of the trial. Again, statistical power was
insufficient to further elaborate on these patterns which may also
be a chance finding.
In sum, this study indicates an association between exposure to
traffic-related air pollution and the progression of atherosclerosis
in humans. While in agreement with cross-sectional findings and
animal studies, these results need to be corroborated with
longitudinal studies particularly designed to evaluate this hypoth-
esis, and to investigate the role of endogenous and exogenous co-
factors that may interact with the vascular toxicity of ambient
pollutants. Future studies should investigate whether atherogenic
effects of air pollution may be larger in women, among the socially
deprived or poorly educated, and possibly among those under
treatments that interact with atherogenic pathways. The issue is of
substantial public health relevance due to the high burden of
morbidity and mortality related to atherosclerosis, and the very
high number of people exposed to ambient air pollutants through
the entire lifecourse.
Supporting Information
Text S1 Supporting material text.
Found at: doi:10.1371/journal.pone.0009096.s001 (0.04 MB
DOC)
Table S1 Missing variable information subject to imputation.
Found at: doi:10.1371/journal.pone.0009096.s002 (0.06 MB
DOC)
Table S2 Description of the exclusion criteria of B-Vitamin
Atherosclerosis Intervention Trial (BVAIT), the Vitamin E
Atherosclerosis Prevention Study (VEAPS), the Estrogen in the
Prevention of Atherosclerosis Trial (EPAT), the Troglitazone
Atherosclerosis Regression Trial (TART), and the Women’s
Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis
Regression Trial (WELL-HART) used in this analyses. (CVD =
cardiovascular diseases; LDL = low density lipids). For inclusion
criteria and main references: see Table 1 in the main manuscript.
Found at: doi:10.1371/journal.pone.0009096.s003 (0.05 MB
DOC)
Table S3 Association between the main markers of air pollution
and CIMT progression among subgroups defined by sex, reported
lipid-lowering medication, and after exclusion of one or two trials,
with p-values for interaction. Coefficients are in micrometers, per
10 ug/m3 PM2.5 or ‘living within 100 m of a highway’,
respectively. (Main model same as in Table 3).
Found at: doi:10.1371/journal.pone.0009096.s004 (0.07 MB
DOC)
Acknowledgments
We like to thank Kimber Watson Nelson for her contribution in getting the
data various organized and for collecting supplementary information in a
subset of the trial participants.
Author Contributions
Conceived and designed the experiments: NK HNH WJM. Performed the
experiments: HNH WJM. Analyzed the data: NK MJ RGE XB.
Contributed reagents/materials/analysis tools: MJ BB FG MM WJM.
Wrote the paper: NK MJ. Initiated project, idea of pooling of 5 trials: NK.
Lead development of all exposure assessment models: MJ. Statistical
advice, contributed to writing the paper: XB. Conducted spatial models for
exposure assessment: BB. Input in analysis strategy, review of manuscript
versions: FG JMP. Reviewed paper: MM. Reviewed and revised
manuscript: HNH. Revised manuscript: WJM.
References
1. Lusis AJ (2000) Atherosclerosis. Nature 407: 233–241.
2. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, et al. (2004) Air pollution
and cardiovascular disease: a statement for healthcare professionals from the
Expert Panel on Population and Prevention Science of the American Heart
Association. Circulation 109: 2655–2671.
3. Ku ¨nzli N, Tager I (2005) Air Pollution: From Lung to Heart. Swiss Med Weekly
135: 697–702.
4. Simkhovich BZ, Kleinman MT, Kloner RA (2008) Air pollution and
cardiovascular injury epidemiology, toxicology, and mechanisms. J Am Coll
Cardiol 52: 719–726.
5. Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, et al. (2002) Particulate
air pollution induces progression of atherosclerosis. J Am Coll Cardiol 39:
935–942.
6. Araujo JA, Barajas B, Kleinman M, Wang X, Bennett BJ, et al. (2008) Ambient
particulate pollutants in the ultrafine range promote early atherosclerosis and
systemic oxidative stress. Circ Res 102: 589–596.
7. Sun Q, Wang A, Jin X, Natanzon A, Duquaine D, et al. (2005) Long-term air
pollution exposure and acceleration of atherosclerosis and vascular inflammation
in an animal model. JAMA 294: 3003–3010.
8. Ku ¨nzli N, Jerrett M, Mack WJ, Beckerman B, LaBree L, et al. (2005) Ambient
air pollution and atherosclerosis in Los Angeles. Environ Health Perspect 113:
201–206.
9. Hoffmann B, Moebus S, Mohlenkamp S, Stang A, Lehmann N, et al. (2007)
Residential exposure to traffic is associated with coronary atherosclerosis.
Circulation 116: 489–496.
10. Allen RW, Criqui MH, Diez Roux AV, Allison M, Shea S, et al. (2009) Fine
particulate matter air pollution, proximity to traffic, and aortic atherosclerosis.
Epidemiology 20: 254–264.
11. Hodis HN, Mack WJ, Zheng L, Li Y, Torres M, et al. (2006) Effect of
peroxisome proliferator-activated receptor gamma agonist treatment on
subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.
Diabetes Care 29: 1545–1553.
Pollution and Atherogenesis
PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e909612. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, et al. (2001) Estrogen in
the prevention of atherosclerosis. A randomized, double-blind, placebo-
controlled trial. Ann Intern Med 135: 939–953.
13. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, et al. (2003) Hormone
therapy and the progression of coronary-artery atherosclerosis in postmeno-
pausal women. N Engl J Med 349: 535–545.
14. Hodis HN, Mack WJ, Dustin L, Mahrer PR, Azen SP, et al. (2009) High-dose B
vitamin supplementation and progression of subclinical atherosclerosis: a
randomized controlled trial. Stroke 40: 730–736.
15. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, et al. (2002) Alpha-
tocopherol supplementation in healthy individuals reduces low-density lipopro-
tein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention
Study (VEAPS). Circulation 106: 1453–1459.
16. Selzer RH, Hodis HN, Kwong-Fu H, Mack WJ, Lee PL, et al. (1994) Evaluation
of computerized edge tracking for quantifying intima-media thickness of the
common carotid artery from B-mode ultrasound images. Atherosclerosis 111:
1–11.
17. Selzer RH, Mack WJ, Lee PL, Kwong-Fu H, Hodis HN (2001) Improved
common carotid elasticity and intima-media thickness measurements from
computer analysis of sequential ultrasound frames. Atherosclerosis 154:
185–193.
18. Health Effects Institute (2009) Traffic-Related Air Pollution: A Critical Review
of the Literature on Emissions, Exposure, and Health Effects. Boston: HEI.
Special Report 17 Special Report 17.
19. Jerrett M, Burnett R, Ma R, Pope AC, Krewski D, Newbold KB, Thuston G,
Shi Y, Finkelstein N, Calle EE, Thun MJ (2005) Spatial analysis of air pollution
and mortality in Los Angeles. Epidemiology 16: 727–736.
20. Bailey TG, A (1995) Interactive Spatial Data Analysis. New York: Longman.
21. Burrough PM, R (1998) Principles of Geographical Information Systems. New
York: Oxford University Press.
22. Hoek G, Fischer P, Van Den Brandt P, Goldbohm S, Brunekreef B (2001)
Estimation of long-term average exposure to outdoor air pollution for a cohort
study on mortality. J Expo Anal Environ Epidemiol 11: 459–469.
23. Jerrett M, Finkelstein MM, Brook JR, Arain MA, Kanaroglou P, et al. (2009) A
cohort study of traffic-related air pollution and mortality in Toronto, Ontario,
Canada. Environ Health Perspect 117: 772–777.
24. Rubin D (1996) Multiple imputation after 18+ years. J Am Stat Assoc 91:
473–489.
25. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Cont Clin Trials
7: 177–188.
26. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, et al. (1998) The role of
carotid arterial intima-media thickness in predicting clinical coronary events.
Ann Intern Med 128: 262–269.
27. Blankenhorn DH, Hodis HN (1994) George Lyman Duff Memorial Lecture.
Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 14: 177–192.
28. Hodis HN, Mack WJ (1999) Carotid artery intima-media thickness and risk of
cardiovascular events. Curr Pract Med 2: 171–174.
29. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, et al. (1999)
Carotid-artery intima and media thickness as a risk factor for myocardial
infarction and stroke in older adults. Cardiovascular Health Study Collaborative
Research Group. N Engl J Med 340: 14–22.
30. Yamawaki H, Iwai N (2006) Mechanisms Underlying Nano-Sized Air-Pollution-
Mediated Progression of Atherosclerosis. Circ J 70: 129–140.
31. Hodis HN (2008) Assessing benefits and risks of hormone therapy in 2008: new
evidence, especially with regard to the heart. Cleve Clin J Med 75 Suppl 4:
S3–12.
32. Brook RD (2008) Cardiovascular effects of air pollution. Clin Sci 115: 175–187.
33. Sharman JE, Coombes JS, Geraghty DP, Fraser DI (2002) Exposure to
automotive pollution increases plasma susceptibility to oxidation. Arch Environ
Health 57: 536–540.
34. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M,
et al. (2005) Secondary prevention of macrovascular events in patients with type
2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In
macroVascular Events): a randomised controlled trial. Lancet 366: 1279–1289.
35. Camasmie Abe K, de Campos Branda ˜o L, Aguilar Calegare B, Tufik S, do
Nascimento Saldiva P, et al. (2009) Homocysteine and cysteine concentrations
are modified by recent exposure to environmental air pollution in Sa ˜o Paulo,
Brazil. Env Research epub ahead of print.
36. Hodis HN, Mack WJ (2008) Postmenopausal hormone therapy and cardiovas-
cular disease in perspective. Clin Obstet Gynecol 51: 564–580.
37. Zhu Y, Hinds WC, Kim S, Sioutas C (2002) Concentration and size distribution
of ultrafine particles near a major highway. J Air Waste Manag Assoc 52:
1032–1042.
38. Nel A (2005) Air Pollution-Related Illness: Effects of Particles. Science 308:
804–806.
39. Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, et al. (2002) Risk
factors for progression of common carotid atherosclerosis: the Atherosclerosis
Risk in Communities Study, 1987-1998. Am J Epidemiol 155: 38–47.
40. Yanez ND 3rd, Kronmal RA, Shemanski LR (1998) The effects of measurement
error in response variables and tests of association of explanatory variables in
change models. Stat Med 17: 2597–2606.
41. Beelen R, Hoek G, Houthuijs D, van den Brandt PA, Goldbohm RA, et al.
(2009) The joint association of air pollution and noise from road traffic with
cardiovascular mortality in a cohort study. Occup Environ Med 66: 243–250.
42. Miller KA, Siscovick DS, Sheppard L, Shepherd K, Sullivan JH, et al. (2007)
Long-term exposure to air pollution and incidence of cardiovascular events in
women. N Engl J Med 356: 447–458.
Pollution and Atherogenesis
PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9096